Trends in Colorectal Cancer Incidence by Anatomic Site and Disease Stage in the United States From 1976 to 2005

Liu, Cheng; Eng, Cathy; Nieman, Linda Z.; Kapadia, Asha S.; Du, Xianglin L.

doi:10.1097/coc.0b013e3181fe41ed

Cited by 207 publications

(163 citation statements)

References 27 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…Due to its huge disease burden, tremendous efforts have been devoted to improving the multidisciplinary treatment strategy of CRC patients. In recent decades, the development in earlier diagnosis through screening and better treatment modalities has obviously decreased the mortality of colorectal cancer (Cheng et al, 2011;Siegel et al, 2011). However, the majority of CRC patients still die from tumor recurrence and metastasis.…”

Section: Introductionmentioning

confidence: 99%

Serum miR-19a Predicts Resistance to FOLFOX Chemotherapy in Advanced Colorectal Cancer Cases

Chen¹,

Xiao²,

Ge³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Colorectal cancer is the fourth most common cancer worldwide and the second leading cause of cancer-related death. FOLFOX is the most common regimen used in the first-line chemotherapy in advanced colorectal cancer, but only half of the patients respond to this regimen and we have almost no clue in predicting resistance in such first-line application. Methods: To explore the potential molecular biomarkers predicting the resistance of FOLFOX regimen as the first-line treatment in advanced colorectal cancer, we screened microRNAs in serum samples from drug-responsive and drug-resistant patients by microarrays. Then differential microRNA expression was further validated in an independent population by reverse transcription and quantitative realtime PCR. Results: 62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis. Among them, 5 (miR-221, miR-222, miR-122, miR-19a, miR-144) were chosen for further validation in an independent population (N=72). Our results indicated serum miR-19a to be significantly up-regulated in resistance-phase serum (p=0.009). The ROC curve analysis showed that the sensitivity of serum miR-19a to discriminate the resistant patients from the response ones was 66.7%, and the specificity was 63.9% when the AUC was 0.679. We additionally observed serum miR-19a had a complementary value for cancer embryonic antigen (CEA). Stratified analysis further revealed that serum miR-19a predicted both intrinsic and acquired drug resistance. Conclusions: Our findings confirmed aberrant expression of serum miR-19a in FOLFOX chemotherapy resistance patients, suggesting serum miR-19a could be a potential molecular biomarker for predicting and monitoring resistance to first-line FOLFOX chemotherapy regimens in advanced colorectal cancer patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum miR-19a Predicts Resistance to FOLFOX Chemotherapy in Advanced Colorectal Cancer Cases

Chen¹,

Xiao²,

Ge³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The test, however, cannot inform as to whether the blood is from the colon or from other parts of the digestive tract (e.g., stomach). Although cancers and polyps can cause blood in stool, other causes of bleeding are ulcers, hemorrhoids, diverticulosis (tiny pouches that form at weak spots in colon wall), or IBDs (colitis] [25,30]. Nonetheless, as blood passes through the gastrointestinal (GI) tract, it becomes degraded, and depending upon the site at which the hemorrhage occurs, blood products detected in the stool by FOBT method will vary.…”

Section: Current Methods For Colon Cancer Screeningmentioning

confidence: 99%

“…Besides, mutations are only found in a portion of the tumors, making the test to be a less sensitive one [45]. avoid nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen (Advil), naproxen (Aleve) or aspirin (> 1 adult aspirin, 325 mg/day) for 7 days before testing as they cause bleeding, although Tylenol ® can be taken as needed, vitamin C in excess of 250 mg/day from all sources, as well as red meats (beef, lamb or liver) for 3 days before testing, because components of blood in meat may give false positive results [1,[18][19][20][29][30][31]. The procedure requires multiple tests to be repeated every year, potentially reducing compliance [23,32].…”

Section: Current Methods For Colon Cancer Screeningmentioning

confidence: 99%

“…This test is easier to use than guaiac FOBT because it requires are no drug or dietary restrictions, and it is less likely to react to bleeding from parts of the upper digestive tract (e.g., stomach) [18,30]. Because like guaiac FOBT, the FIT may not react to a tumor that is not bleeding [32], multiple stool samples are needed for testing, and if results are positive, a colonoscopy will also be required.…”

Section: Current Methods For Colon Cancer Screeningmentioning

confidence: 99%

“…Data from Peking Union Medical College Hospital, China indicated that colon & rectal cancers accounted for 55.6% and 44.4% of CRC, respectively during the years 1989 through 2008, and are more prevalent in younger Asian individuals [2]. In contrast, CC was shown to account for over 60% of CRC cases in the USA & Europe, and is related to fatty foods, less exercise and a Caucasian ethnic origin [3][4][5][6], which suggest differences in carcinogenesis between CC and RC. Several structural and molecular studies have indicated differences in etiology, clinical manifestation, pathological features and genetic abnormalities between CC & RC [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

MicroRNAs as molecular markers for colon cancer Diagnostic screening in stool & blood

Ahmed¹,

Ahmed²

2017

Med Res Innov

View full text Add to dashboard Cite

Screening for colon cancer (CC) allows for diagnosis of the early stage for malignancy and potentially reduces disease mortality as the cancer could be cured at disease earliest stages. Early detection could be desirable if accurate, practical and cost effective diagnostic measures for this cancer are available. Mortality and morbidity from colon cancer represent a major health problem involving a malignant disease that is theoretically preventable through screening. Current screening methods (e.g., the immunological fecal occult blood test, FOBTi, obtained from patients' medical records) either lacks sensitivity and requires dietary restriction, which impedes compliance and use; are costly (e.g., colonoscopy), which decreases compliance; or could lead to mortality. In comparison to the FOBT test, a noninvasive sensitive screen for which there is no requirement for dietary restriction would be a more convenient test. Colorectal cancer (CRC) is the only cancer for which screening by colonoscopy is recommended. Although colonoscopy is a reliable screening tool, its invasive nature, accompanying abdominal pain, potential complications and high cost have hampered the application of this screening method worldwide.A novel screening approach using the stable miRNA molecules, which are relatively nondegradable when extracted from noninvasive stool and semi-invasive blood samples by currently available commercial kits and manipulated thereafter, would be preferable to a transcriptomic messenger (m)RNA-, a mutation DNA-, an epigenetic-or a proteomic-based test. The approach utilizes reverse transcriptase (RT), followed by a modified quantitative real-time polymerase chain reaction (qPCR). Although exosomal RNA would not be measured, using a restricted extraction of total RNA from stool or blood, then a parallel test could also be carried out on RNA obtained from stool or plasma samples, and appropriate corrections for exsosomal loss can be made to obtain accurate and quantitative results. Eventually, a chip would be developed to facilitate diagnosis, as has been carried out for the quantification of genetically modified organisms (GMOs) in foods. The gold standard to which the molecular miRNA test is compared is colonoscopy. If performance criteria are met, as detailed herein, then a miRNA test in human stool or blood samples based on high throughput automated technologies and quantitative expression measurements --commonly used in the diagnostic clinical laboratory--would eventually be advanced to the clinical setting, which will make a vivid impact on the prevention of colon cancer.Correspondence to: Farid E. Ahmed, GEM

show abstract

Risk of Primary Tumor Sidedness as a Criterion for Screening, Diagnostic Colonoscopy, and Surveillance Intervals—Reply

2017

View full text Add to dashboard Cite

show abstract

Trends in Colorectal Cancer Incidence by Anatomic Site and Disease Stage in the United States From 1976 to 2005

Cited by 207 publications

References 27 publications

Serum miR-19a Predicts Resistance to FOLFOX Chemotherapy in Advanced Colorectal Cancer Cases

Serum miR-19a Predicts Resistance to FOLFOX Chemotherapy in Advanced Colorectal Cancer Cases

MicroRNAs as molecular markers for colon cancer Diagnostic screening in stool & blood

Risk of Primary Tumor Sidedness as a Criterion for Screening, Diagnostic Colonoscopy, and Surveillance Intervals—Reply

Contact Info

Product

Resources

About